| scholarly article | Q13442814 |
| P2093 | author name string | Shuo Zhang | |
| Jasvinder K Atwal | |||
| Ryan J Watts | |||
| Yichin Liu | |||
| Amy Gustafson | |||
| James A Ernst | |||
| Pascal Steiner | |||
| Marcel van der Brug | |||
| Janice A Maloney | |||
| Roxanne Kyauk | |||
| Travis Bainbridge | |||
| P2860 | cites work | TREM2 Variants in Alzheimer's Disease | Q22250873 |
| Variant of TREM2 Associated with the Risk of Alzheimer's Disease | Q22250874 | ||
| A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 | ||
| APP binds DR6 to trigger axon pruning and neuron death via distinct caspases | Q22251088 | ||
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families | Q28732285 | ||
| Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease | Q28943325 | ||
| Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease | Q29614374 | ||
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | Q29614879 | ||
| Codon 618 variant of alzheimer amyloid gene associated with inherited cerebral hemorrhage | Q33155348 | ||
| The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation | Q34088689 | ||
| Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production | Q34280406 | ||
| Human apoE isoforms differentially regulate brain amyloid-β peptide clearance | Q35334161 | ||
| β- but not γ-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia | Q36037957 | ||
| Amyloid precursor protein mutation E682K at the alternative β-secretase cleavage β'-site increases Aβ generation | Q36038732 | ||
| Inhibition of γ-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia | Q36124692 | ||
| The role of microglia in amyloid clearance from the AD brain | Q36841789 | ||
| Preparing Synthetic Aβ in Different Aggregation States | Q37119634 | ||
| Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease | Q37149705 | ||
| A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. | Q37309370 | ||
| The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes | Q37979641 | ||
| Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. | Q43697159 | ||
| Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation | Q48237916 | ||
| Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type | Q48265529 | ||
| Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease | Q48493687 | ||
| Presenilin mutations line up along transmembrane alpha-helices. | Q52543234 | ||
| An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. | Q53207278 | ||
| Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. | Q53237015 | ||
| A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. | Q53391715 | ||
| Estimation of the Genetic Contribution of Presenilin-1 and -2 Mutations in a Population-Based Study of Presenile Alzheimer Disease | Q57419118 | ||
| Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch) | Q57849311 | ||
| Novel Leu723Pro amyloid precursor protein mutation increases amyloid beta42(43) peptide levels and induces apoptosis | Q73425524 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 30990-31000 | |
| P577 | publication date | 2014-09-24 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein | |
| P478 | volume | 289 |
| Q48956120 | A2T and A2V Aβ peptides exhibit different aggregation kinetics, primary nucleation, morphology, structure, and LTP inhibition |
| Q41582196 | APP mouse models for Alzheimer's disease preclinical studies |
| Q37053876 | AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics |
| Q89657808 | Aggregation Mechanism of Alzheimer's Amyloid β-Peptide Mediated by α-Strand/α-Sheet Structure |
| Q35050571 | Alzheimer's protective A2T mutation changes the conformational landscape of the Aβ₁₋₄₂ monomer differently than does the A2V mutation |
| Q39405747 | Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer's disease: inseparable partners in a multifactorial disease |
| Q33893017 | Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies |
| Q36199818 | Amyloid β-Protein Assembly: Differential Effects of the Protective A2T Mutation and Recessive A2V Familial Alzheimer's Disease Mutation |
| Q47726298 | BACE1 Cleavage Site Selection Critical for Amyloidogenesis and Alzheimer's Pathogenesis. |
| Q47658329 | BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer's Disease Pathology. |
| Q38332419 | BACE1 inhibitor drugs in clinical trials for Alzheimer's disease |
| Q92287758 | BACE1 partial deletion induces synaptic plasticity deficit in adult mice |
| Q34477381 | CALHM1 ion channel elicits amyloid-β clearance by insulin-degrading enzyme in cell lines and in vivo in the mouse brain |
| Q40972124 | Characterization of FRM-36143 as a new γ-secretase modulator for the potential treatment of familial Alzheimer's disease. |
| Q40335498 | Characterization of genetic variation in TLR8 in relation to allergic rhinitis |
| Q45300233 | Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease |
| Q52686864 | Differential effect of amyloid beta peptides on mitochondrial axonal trafficking depends on their state of aggregation and binding to the plasma membrane. |
| Q41566107 | Emergence of Alternative Structures in Amyloid Beta 1-42 Monomeric Landscape by N-terminal Hexapeptide Amyloid Inhibitors |
| Q39039911 | Excess APP O-glycosylation by GalNAc-T6 decreases Aβ production |
| Q39047085 | From Common to Rare Variants: The Genetic Component of Alzheimer Disease. |
| Q93037059 | Galectin 3-binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein |
| Q38559613 | Generation of aggregation prone N-terminally truncated amyloid β peptides by meprin β depends on the sequence specificity at the cleavage site |
| Q26747803 | Genes associated with Alzheimer's disease: an overview and current status |
| Q39047624 | Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease |
| Q42321743 | Gleevec shifts APP processing from a β-cleavage to a nonamyloidogenic cleavage |
| Q47124444 | Human Induced Pluripotent Stem Cells and the Modelling of Alzheimer's Disease: The Human Brain Outside the Dish |
| Q28081278 | Immunotherapeutic approaches for Alzheimer's disease |
| Q61798848 | Important advances in Alzheimer's disease from the use of induced pluripotent stem cells |
| Q47280385 | Increased Foxo3a Nuclear Translocation and Activity is an Early Neuronal Response to βγ-Secretase-Mediated Processing of the Amyloid-β Protein Precursor: Utility of an AβPP-GAL4 Reporter Assay |
| Q48175839 | Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology |
| Q38851332 | Ion channel regulation by β-secretase BACE1 - enzymatic and non-enzymatic effects beyond Alzheimer's disease. |
| Q46819526 | Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer's disease |
| Q92483746 | Modeling Alzheimer's disease with iPSC-derived brain cells |
| Q38374439 | Modulation in the conformational and stability attributes of the Alzheimer's disease associated amyloid-beta mutants and their favorable stabilization by curcumin: molecular dynamics simulation analysis |
| Q38796950 | Network abnormalities and interneuron dysfunction in Alzheimer disease |
| Q93336516 | Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA 5'-untranslated region: Implications in Alzheimer's disease |
| Q89544702 | Opposite changes in APP processing and human Aβ levels in rats carrying either a protective or a pathogenic APP mutation |
| Q64970966 | Packing Density of the Amyloid Precursor Protein in the Cell Membrane. |
| Q64087524 | Processing of Mutant β-Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer's Disease |
| Q38616791 | Protective alleles and modifier variants in human health and disease |
| Q46881256 | Rare variants in dementia genes and Parkinson's disease |
| Q47703114 | Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells |
| Q41555225 | Role of BACE1 in Alzheimer's synaptic function. |
| Q52582953 | Serotonin, beta-amyloid, and cognition in Parkinson disease. |
| Q33796378 | Stem cell models of Alzheimer's disease: progress and challenges |
| Q89841161 | Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2 |
| Q36569888 | Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid-β. |
| Q36247247 | The A673T mutation in the amyloid precursor protein reduces the production of β-amyloid protein from its β-carboxyl terminal fragment in cells |
| Q36037502 | The APP A673T frequency differs between Nordic countries |
| Q54977832 | The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. |
| Q39222469 | The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients |
| Q39432793 | The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model |
| Q39095782 | The Metalloprotease Meprin β Is an Alternative β-Secretase of APP. |
| Q47942319 | The Pathogenic A2V Mutant Exhibits Distinct Aggregation Kinetics, Metal Site Structure, and Metal Exchange of the Cu2+ -Aβ Complex. |
| Q55381143 | The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. |
| Q38676359 | The Triggering Receptor Expressed on Myeloid Cells 2: A Molecular Link of Neuroinflammation and Neurodegenerative Diseases |
| Q26749528 | The amyloid hypothesis of Alzheimer's disease at 25 years |
| Q36664193 | Visualizing APP and BACE-1 approximation in neurons yields insight into the amyloidogenic pathway. |
| Q48132232 | Widespread brain distribution and activity following i.c.v. infusion of anti-β-secretase (BACE1) in nonhuman primates. |
Search more.